Robert A. Lafyatis, MD
Adjunct Professor
Boston University School of Medicine
Dept of Medicine
Rheumatology

MD, University of Cincinnati




Dr. Lafyatis carries out patient oriented research into the cause and treatment of systemic sclerosis. This includes early phase clinical trials into new therapeutic agents in patients with systemic sclerosis. He has been investigating the mechanisms of actions and markers of response for novel therapeutics, such as the B cell depleting agent, rituximab and the immunosuppressant agent, mycophenlate. Additional studies are aimed at identifying biomarkers in systemic sclerosis using microarray gene expression analysis of skin and blood in scleroderma patients. Ongoing biomarker studies include investigation into molecular markers of pulmonary hypertension in systemic sclerosis. Dr. Lafyatis also carries out basic research into the cause of fibrosis and vasculopathy in systemic sclerosis using patient samples and murine disease models. His studies have provided key insights into one widely used model of systemic sclerosis, the tight skin mouse. His studies are currently focused on understanding how autoimmunity and the innate immune system lead to fibrosis and vascular damage. This has recently led to the discovery of increased interferon-regulated gene expression in white blood cells of patients with systemic sclerosis. Ongoing research is aimed at better understanding the cause of altered gene expression by monocytes and other cells in the innate immune system.

Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
12/01/2015 - 11/30/2021 (Co-Investigator)
PI: Robert W. Simms, MD
Corbus Pharmaceuticals Holdings, Inc.


A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy volunteers and Subjects with Systemic Lupus Erythematosus
04/09/2015 - 04/08/2020 (Co-Investigator)
PI: Christina Lam, MD
Biogen Idec


Scleroderma Clinical Repository (SCaR)
10/01/2014 - 09/30/2019 (PI)
Regeneron Pharmaceuticals, Inc.


ASSET: A Phase II study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis - a double-blind, placebo-controlled, randomized controlled trial [IMI101-344]
03/31/2015 - 06/30/2019 (Subcontract PI)
Regents of the University of Michigan Bristol-Myers Squibb


Randomized, double-blind, placebo-controlled trial of IL1-Trap, Rilonacept, in Systemic Sclerosis-A Phase I/II Biomarker Trial
12/01/2011 - 02/05/2019 (PI)
Regeneron Pharmaceuticals, Inc.


Scleroderma Workshop
02/01/2010 - 01/31/2018 (PI)
MedImmune, Inc.


Nox4 Inhibitor in Systemic Sclerosis
11/14/2014 - 11/13/2017 (PI)
Mistral Therapeutics, Inc.


NIAMS: CORT
09/01/2011 - 08/31/2017 (PI of Sub-Project / SP)
PI: Robert W. Simms, MD
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5P50AR060780-05

Rheumatic Diseases Research Core Centers
09/01/2011 - 08/31/2017 (PI of Sub-Project / SP)
PI: Robert W. Simms, MD
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5P30AR061271-05

A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis-A Phase I/II Biomarker and Safety Trial
04/02/2015 - 04/01/2017 (PI)
PRISM Pharma Co Ltd


Showing 10 of 42 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs
2021 Mapping Age-Related Changes in the Lung 7U01HL145550-03
2021 NIAMS: Center for Research Translation (CORT) 3P50AR060780-09S1 80
2021 Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis 5P50AR060780-10 80
2021 Administrative Core 5P50AR060780-10-6914 80
2021 Project 1: Systemic Sclerosis Skin Biomarkers & Therapeutics 5P50AR060780-10-6918 80
2021 Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis 3P50AR060780-10S1 80
2020 Mapping Age-Related Changes in the Lung 5U01HL145550-02
2020 Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis 5P50AR060780-09 80
2020 Administrative Core 5P50AR060780-09-6914 80
2020 Project 1: Systemic Sclerosis Skin Biomarkers & Therapeutics 5P50AR060780-09-6918 80
Showing 10 of 70 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Snyder ME, Moghbeli K, Bondonese A, Craig A, Popescu I, Fan L, Tabib T, Lafyatis R, Chen K, Trejo Bittar HE, Lendermon E, Pilewski J, Johnson B, Kilaru S, Zhang Y, Sanchez PG, Alder JK, Sims PA, McDyer JF. Modulation of tissue resident memory T cells by glucocorticoids after acute cellular rejection in lung transplantation. J Exp Med. 2022 Apr 04; 219(4). PMID: 35285873; PMCID: PMC8924935; DOI: 10.1084/jem.20212059;
     
  2. Xue D, Tabib T, Morse C, Yang Y, Domsic RT, Khanna D, Lafyatis R. Expansion of Fc? Receptor IIIa-Positive Macrophages, Ficolin 1-Positive Monocyte-Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis. Arthritis Rheumatol. 2022 02; 74(2):329-341. PMID: 34042322; PMCID: PMC8626521; DOI: 10.1002/art.41813;
     
  3. Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021 12 17; 12(1):7338. PMID: 34921143; PMCID: PMC8683505; DOI: 10.1038/s41467-021-27619-4;
     
  4. Jussila AR, Zhang B, Caves E, Kirti S, Steele M, Hamburg-Shields E, Lydon J, Ying Y, Lafyatis R, Rajagopalan S, Horsley V, Atit RP. Skin Fibrosis and Recovery Is Dependent on Wnt Activation via DPP4. J Invest Dermatol. 2022 Jun; 142(6):1597-1606.e9. PMID: 34808238
     
  5. Domsic RT, Gao S, Laffoon M, Wisniewski S, Zhang Y, Steen V, Lafyatis R, Medsger TA. Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design. Rheumatology (Oxford). 2021 10 02; 60(10):4662-4670. PMID: 33506859; PMCID: PMC8677444; DOI: 10.1093/rheumatology/keab075;
     
  6. Rodor J, Chen SH, Scanlon JP, Monteiro JP, Caudrillier A, Sweta S, Stewart KR, Shmakova A, Dobie R, Henderson BEP, Stewart K, Hadoke PWF, Southwood M, Moore SD, Upton PD, Morrell NW, Li Z, Chan SY, Handen A, Lafyatis R, de Rooij LPMH, Henderson NC, Carmeliet P, Spiroski AM, Brittan M, Baker AH. Single-cell RNA-seq profiling of mouse endothelial cells in response to pulmonary arterial hypertension. Cardiovasc Res. 2021 Sep 16. PMID: 34528097
     
  7. Blobner BM, Saloman JL, Shelton Ohlsen CA, Brand R, Lafyatis R, Bottino R, Wijkstrom M, Zureikat AH, Lee KK, Singhi AD, Ross MA, Stolz D, Whitcomb DC. Single-cell analyses of human pancreas: characteristics of two populations of acinar cells in chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2021 11 01; 321(5):G449-G460. PMID: 34523348; PMCID: PMC8616588; DOI: 10.1152/ajpgi.00482.2020;
     
  8. Moghbeli K, Valenzi E, Naramore R, Sembrat JC, Chen K, Rojas MM, Wenzel SE, Lafyatis R, Modena B, Weathington NM. ß-Agonist exposure preferentially impacts lung macrophage cyclic AMP-related gene expression in asthma and asthma COPD overlap syndrome. Am J Physiol Lung Cell Mol Physiol. 2021 11 01; 321(5):L837-L843. PMID: 34494468; PMCID: PMC8616616; DOI: 10.1152/ajplung.00260.2021;
     
  9. Lescoat A, Roofeh D, Kuwana M, Lafyatis R, Allanore Y, Khanna D. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clin Rev Allergy Immunol. 2021 Sep 01. PMID: 34468946; PMCID: PMC9034469; DOI: 10.1007/s12016-021-08891-0;
     
  10. Cruz T, Jia M, Sembrat J, Tabib T, Agostino N, Bruno TC, Vignali D, Sanchez P, Lafyatis R, Mora AL, Benos P, Rojas M. Reduced Proportion and Activity of Natural Killer Cells in the Lung of Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 09 01; 204(5):608-610. PMID: 34077698; PMCID: PMC8491266; DOI: 10.1164/rccm.202012-4418LE;
     
Showing 10 of 214 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 214 publications over 33 distinct years, with a maximum of 17 publications in 2016 and 2021

YearPublications
19881
19897
19908
19919
19921
19932
19944
19961
19971
19982
19992
20001
20024
20031
20043
20052
20067
20078
20084
20098
201014
20115
201210
201310
20149
20159
201617
20179
201810
201913
202013
202117
20222

Contact for Mentoring:

75 E. Newton St Evans Building
Boston MA 02118
Google Map


Lafyatis's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department